ArticleScience advances2026
Bacteriocin-transport-inspired oral peptide-probiotic delivery ameliorates IBD complications via autophagy and gut homeostasis.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biohybrid M13 phage backpacks for active blood-brain barrier traversal and precision central nervous system leukemia treatment.Biomarker research · 2026Article
- Probiotics and Extracellular Vesicles as Redox Modulators in Wound Healing: From Microbial Therapeutics to Engineered Nanotherapeutic Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- Bacteriocins as precision antimicrobials: genomic exploration and oral applications of Lactobacillus peptides.Archives of microbiology · 2026Review
- Autophagy: mechanisms, roles in human diseases, and therapeutic perspectives.Frontiers in cell and developmental biology · 2026Review
- Topological characteristics and longitudinal dynamics of co-abundance networks involving beneficial commensal bacteria in the pig gut microbiome and its association with average daily gain.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal fibrosis (IF), a severe complication of inflammatory bowel disease (IBD), remains a critical unmet clinical need. Although the LL37 peptide and probiotics demonstrate therapeutic potential against IF, their clinical translation is hampered by enzymatic hydrolysis and rapid clearance. Here, inspired by the strategy of bacteriocin transport by bacteria (BTB), we developed an orally administered biotherapeutic platform [BTB-alginate (Alg)] featuring an "all-in-one" architecture that enables spatiotemporal coordination of LL37 and probiotics. The BTB-Alg effectively restored intestinal homeostasis through inflammation resolution, immune modulation, and gut microbiota reconstitution. Notably, integrated multiomics analysis and molecular dynamics simulations revealed that LL37 exerts antifibrotic effects by inducing adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin-mediated autophagy, a mechanism validated in clinical specimens. BTB-Alg exhibited potent therapeutic efficacy in three murine models of acute colitis, IBD-associated IF, and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.